Teclison is dedicated to the development of new drugs to treat cancer and other diseases with strong unmet medical need

Our Focus

The initial focus is on liver cancer or hepatocellular carcinoma (HCC) based on the platform technology in targeting tumor vessels to induce tumor hypoxia, and then expanded to other solid tumors.

What Is Liver Cancer

Liver cancer or hepatocellular carcinoma has an incidence of over 22,000 cases per year in the United States and over 800,000 cases worldwide. China and Asian countries have the highest incidence of HCC, with HCC ranked as a top cause of death. More interestingly, HCC is one cancer that has been steadily increasing over the last 10 years. Treatment options, including surgical resection, alcohol injection, radiofrequency ablation, chemoembolization and systemic agents, are far from satisfactory. Among them, embolization is the most commonly use modality, but has no major progress in efficacy over 30 years, and poses a strong unmet medical need. The reason is due to the fact that hypoxia induced by embolization is a double edge sword, although hypoxia can kill tumor cells to show clinical response on the surface, but it also leads to undesirable consequences such as increase new vessel formation and generation of cancer stem cells, which are refractory to standard chemotherapy as show below. A new approach to improve the therapeutic efficacy of embolization is needed.

TPZ

Hepatocellular carcinoma (HCC) is the most common form of liver cancer in adults. TPZ is a first-in-class compound, meaning that it is the first agent with similar mechanism aiming to treat HCC.  The mechanism is that it is only activated in the hypoxic or a low oxygen environment, whereas no activity can be seen in the normal oxygen condition. TPZ combined with embolization (TATE) creates a persistent hypoxic environment selectively in tumor to activate the compound; whereas normal liver or other organs are not lack of oxygen, and not able to activate the compound to induce any side effect in normal organs.  Therefore, TPZ becomes a selective against liver cancer.  The design of our studies is highly innovative and has never been done previously.  Teclison has full confidence that this new strategy will significantly improve the therapeutic effect of embolization to benefit patients with liver cancer.